Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | ESRRG | P62508 | 3/20 | 0.43 |
| ▸ | ESRRB | O95718 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | F13A1 | P00488 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6388384 | 0.83 | ALDH1A1 (0.53) | MLYCDESRRGESRRBLMNAALDH1A1 | |
| SCHEMBL3837907 | 0.82 | CA12 (0.49) | LMNAALDH1A1POLBSMN1; SMN2KDM4E | |
| SCHEMBL3880596 | 0.82 | EPHX1 (0.52) | OPRK1LMNAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL3196978 | 0.81 | MLYCD (0.54) | MLYCDESRRGLMNAALDH1A1POLB | |
| SCHEMBL27553724 | 0.81 | ST14 (0.48) | ESRRGESRRBLMNAALDH1A1POLB | |
| SCHEMBL10887210 | 0.81 | MLYCD (0.47) | MLYCDESRRGESRRBLMNAALDH1A1 | |
| SCHEMBL3005286 | 0.81 | MGLL (0.56) | MLYCDLMNAMTNR1AMTNR1BALDH1A1 | |
| SCHEMBL14141265 | 0.80 | NPC1 (0.59) | ALDH1A1POLBSMN1; SMN2KDM4EF13A1 | |
| SCHEMBL4179064 | 0.78 | HPGD (0.57) | LMNAALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6433557 | 0.78 | KDM4E (0.61) | ESRRGESRRBALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065490-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| EP-1529038-B1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-10-07 | — | — | EP | disclosed |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | CUENOUD BERNARD | 2007-10-25 | — | — | US | disclosed |
| US-20060106075-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | NOVARTIS AG (CH) | 2006-05-18 | — | — | US | disclosed |
| EP-1529038-A1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | Novartis AG (CH) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004016601-A1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | MLYCD 3902/4885OPRK1 20/4885ESRRG 791/4885 |
| US-20060106075-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | MLYCD 3902/4885OPRK1 20/4885ESRRG 791/4885 |
| US-20150065490-A1 | ORGANIC COMPOUNDS | ADRB2, ADRA2C, ADRB1 | MLYCD 2282/4885OPRK1 16/4885ESRRG 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.